Nh Investment And Securities 1p (005945 KO) stock market data APIs
₩12460
-60(-0.5%)
as of January 21, 2025
Nh Investment And Securities 1p Financial Data Overview
Price chart is built with
Anychart
NH Investment & Securities Co., Ltd. engages in the wealth management, investment banking, trading, and equity sales businesses in South Korea and internationally. The company provides a range of investment products and asset management services, including stocks, funds, and ELS/DLS; corporate finance services, such as debt capital market, equity capital market; and digital sale services. It also invests and trades in, and sells equity, bonds, and FICC derivative products. The company was formerly known as Woori Investment & Securities Co., Ltd. and changed its name to NH Investment & Securities Co., Ltd. in December 2014. NH Investment & Securities Co., Ltd. was incorporated in 1969 and is based in Seoul, South Korea. NH Investment & Securities Co., Ltd. operates as a subsidiary of NongHyup Financial Group Inc.
Prev. Close
12520
Open
12460
Volume
52 088
High
12590
Low
12420
52 wk Range
8834.8696-12590
Market Cap
4 883 002 M
Shares Outstanding
18 871 K
Revenue
11 580 589 M
Dividends (Yield)
0.0696
Beta
0.963
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nh Investment And Securities 1p data using free add-ons & libraries
Get Nh Investment And Securities 1p Fundamental Data
Nh Investment And Securities 1p Fundamental data includes:
- Net Revenue: 11 580 589 M
- EBITDA: 0
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-24
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nh Investment And Securities 1p News
New
ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment...
UNLIMEAT Kimbap Products Now Available via DoorDash's DashMart
- UNLIMEAT is now being sold on DoorDash's DashMart, the company's online convenience store, to make UNLIMEAT Kimbap available nationwide. LOS ANGELES, May 30, 2024 /PRNewswire/ -- Frozen kimbap ha...
UNLIMEAT Pulled Pork Wrap Now Available at All Starbucks Stores in HK
Starting April 16th, Starbucks launched UNLIMEAT pulled pork wrap as its newest plant-based option. UNLIMEAT's Starbucks collaboration is the most recent in a series of collaborations between UNLIMEA...
ImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide for Dermatomyositis/Polymyositis
SEOUL, South Korea, Oct. 17, 2023 /PRNewswire/ -- ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic pr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
